Peer-influenced content. Sources you trust. No registration required. This is HCN.

OBR OncologyGSK’s Blood Cancer Drug Fails Main Goal of Trial, Shares Fall

To gain access to its primary experimental medication for a rare blood cancer and complement Blenrep, currently indicated as a treatment for patients with relapsed or refractory multiple myeloma who received at least four prior therapies, the company decided to purchase American pharmaceutical company Sierra Oncology in April. However, in patients with relapsed or refractory multiple myeloma, Blenrep did not achieve the primary endpoint of progression-free survival, according to a statement from GSK, which saw its shares fall 3% upon the announcement.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form